TITLE:
      Buprenorphine Dosing Interval - 5
SUMMARY:
      The purpose of this study is to explore the feasibility of extending the dosing interval of
      well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week
      dosing.
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

        M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within
        the last 30 days. Agreeable to conditions of study and signed informed consent.

        Exclusion Criteria:

        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant
        and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics.
        Acute hepatitis. Other medical conditions that deem participation to be unsafe.
